Abstracts tagged "Disease Activity"

Abstract Number: 668 • 2015 ACR/ARHP Annual Meeting
Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Jolanda Luime¹, Ilja Tchetverikov², Marijn Vis³, Cathelyne Appels⁴, Wiebo van der Graaff⁵, Josien Veris⁶, Andreas Gerards⁷, Hans van Groenendaal⁸, Mark Kok⁹, Lindy-Anne Korswagen¹⁰, Cor Stolk¹¹ and Cicero, ¹Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ³Rheumatology, ErasmusMC, Rotterdam, Netherlands, ⁴Rheumatology, Amphia Hospital, Breda, Netherlands, ⁵Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁶Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁷Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Maasstadweg 21, Maasstad Ziekenhuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Sint Fransicus Gasthuis, Rotterdam, Netherlands, ¹¹-, Patient Partner, Bunnink, Netherlands
Background/Purpose: Several disease activity measures were developed for use in psoriatic arthritis (PsA) . Little data is available on their performance in usual care. This…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 1743 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Ankylosing Spondylitis: Men Derive Greater Benefit from Tumor Necrosis Factor Alpha Inhibitors
Jennifer Mandal¹, Michael M. Ward², Michael Weisman³, Jillian Simard⁴, Matthew A. Brown⁵, MinJae Lee⁶, Mohammad H. Rahbar⁷, John D. Reveille⁸ and Lianne S. Gensler⁹, ¹Medicine, University of California San Francisco, San Francisco, CA, ²NIH/NIAMS, Bethesda, MD, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ⁷The University of Texas Health Science Center at Houston, Houston, TX, ⁸Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) manifests differently in men and women. Women with AS have less severe radiographic disease, yet tend to report more severe symptoms.…
Abstract Number: 2490 • 2015 ACR/ARHP Annual Meeting
Implementation of Disease Activity Measurement for Rheumatoid Arthritis Patients in an Academic Rheumatology Clinic
Alison Bays¹, Elizabeth R. Wahl², David I. Daikh³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Rheumatology, University of Washington, Seattle, WA, ²Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁴Rheumatology, UCSF, SF, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Current recommendations for optimal rheumatoid arthritis (RA) management include routine assessment of disease activity and adjustment of medication to achieve remission or low disease…
Abstract Number: 2643 • 2015 ACR/ARHP Annual Meeting
Decreased Pain Level with Aging Leads to Underestimation of Disease Activity in Rheumatoid Arthritis
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng³, Jason Lyons⁴, Anthony Fabio⁵ and Larry W. Moreland⁶, ¹Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Epidemiology, Univ of Pittsburgh, Pittsburgh, PA, ⁴School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁵Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is most prevalent in those who are 60 years of age or older. It has not been clearly established whether…
Abstract Number: 2901 • 2015 ACR/ARHP Annual Meeting
Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis
Gabriella Lakos¹, John G. Hanly², Peter Martis¹, Chelsea Bentow¹, Milagros Garcia³, Odette Viñas³, Gerard Espinosa⁴, Ricard Cervera⁴ and Michael Mahler⁵, ¹Research, Inova Diagnostics, San Diego, CA, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Immunology, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ⁵Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-dsDNA antibodies support the diagnosis of systemic lupus erythematosus (SLE), and their quantification is useful for the assessment of lupus nephritis (LN) and the…
Abstract Number: 3257 • 2015 ACR/ARHP Annual Meeting
The Link Between DAS28 and the Short-Term Risk of Acute Coronary Syndrome in RA, and Its Driving Factors
Lotta Ljung^1,2, Thomas Frisell³ and Johan Askling^3,4, ¹Department of Medicine, Solna, Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: The extent to which a short-term effect of the disease activity adds to the over-risk of coronary events in patients with Rheumatoid Arthritis (RA)…
Abstract Number: 457 • 2015 ACR/ARHP Annual Meeting
RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
Marcia S. Genta¹, Amnon Sonnenberg² and Robert M. Genta³, ¹Dallas Arthritis Center, Dallas, TX, ²Medicine - Gastroenterology, Portland VAMC - Oregon Health & Science University, Portland, OR, ³Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: We have previously shown that patients with Medicare only coverage without financial assistance from foundations were significantly less likely to receive Biologics than patients…
Abstract Number: 678 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Activity in Psoriatic Arthritis Patients with Dactylitis or Enthesitis: Results from Corrona Registry
Philip J. Mease¹, Chitra Karki², Carol J. Etzel^2,3, Arthur Kavanaugh⁴, Christopher T. Ritchlin⁵, Wendi Malley², Vivian Herrera⁶, Jacqueline B. Palmer⁶ and Jeffrey D. Greenberg^2,7, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴University of California San Diego, La Jolla, CA, ⁵Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷New York University School of Medicine, Millburn, NJ
Background/Purpose: Psoriatic arthritis (PsA) exhibits considerable heterogeneity in its presentation and course, which contributes to the complexity of diagnosis and assessment. Enthesitis, inflammation at the…
Abstract Number: 1241 • 2015 ACR/ARHP Annual Meeting
Identification and Validation of Diagnostic and Activity Urinary Metabolomic Biomarkers in Immune-Mediated Inflammatory Diseases
Arnald Alonso¹, Jesús Tornero², Antonio Fernandez-Nebro³, Juan D. Cañete⁴, Eugeni Domènech⁵, Javier P. Gisbert⁶, Carlos Ferrándiz⁵, Eduardo Fonseca⁷, Valle García⁸, Francisco Blanco⁷, Jesus Rodriguez⁹, Jordi Gratacós¹⁰, Patricia E. Carreira¹¹, Antonio Julià¹, Raül Tortosa¹, Maria López-Lasanta¹², Xavier Correig¹³ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ⁴Unitat d’Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pí i Sunyer, Barcelona, Spain, ⁵Hospital Universitari Germans Trias I Pujol, Badalona, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Complejo Hospitalario Juan Canalejo, A Coruña, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁰Hospital Parc Taulí, Sabadell, Spain, ¹¹Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹³CIBERDEM, Metabolomics Platform, Reus, Spain
Background/Purpose: The recent advances in metabolomics have allowed the study of the regulatory processes linked to metabolism. The comprehensive analysis of the metabolome in biological samples…
Abstract Number: 1826 • 2015 ACR/ARHP Annual Meeting
Small LDL-P Increases with Increased Disease Activity in SLE
Laura Durcan¹, Deborah Winegar², Margery Connelly², James Otvos², Laurence S Magder³ and Michelle Petri¹, ¹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ²LabCorp, Raleigh, NC, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) associates with accelerated atherosclerotic cardiovascular (CV) disease which is not fully explained by traditional CV risk factors. Disease activity, prednisone…
Abstract Number: 2491 • 2015 ACR/ARHP Annual Meeting
Documentation of Disease Activity Score As Part of a Treat to Target Strategy in Rheumatoid Arthritis
Sarah Homann¹ and Beth Scholz², ¹Rheumatology, University of Texas Health Sciences Center at Houston, Houston, TX, ²University of Texas Health Sciences Center at Houston, Houston, TX
Background/Purpose: Compared to routine care, the Treat to Target (TTT) strategy for rheumatoid arthritis (RA) has been validated to improve functional and radiographic outcomes via…
Abstract Number: 2644 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Disease Activity and Cognitive Impairment in Patients with Rheumatoid Arthritis
Sang-Il Lee¹, Young Sun Suh¹, Yun-Hong Cheon¹, Hyun-Ok Kim¹, Hyun-Su Yang², Ki-Soo Park², Eun-Kyoung Park³, Seung-Geun Lee⁴, Chang-Nam Son⁵, Ji-Min Kim⁵ and Sang-Hyon Kim⁶, ¹Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ²Department of Preventive Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Busan National University School of Medicine, Busan, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Only few studies investigated the prevalence and risk factors of cognitive impairment in patients with rheumatoid arthritis (RA), however, results are controversial. Therefore we…
Abstract Number: 2914 • 2015 ACR/ARHP Annual Meeting
Modifiable and Non-Modifiable Correlates of Satisfaction with Care in Systemic Lupus Erythematosus
Syed Alam¹, Nisarg Gandhi², Alana Nevares¹, Ailda Nika², Winston Sequeira² and Meenakshi Jolly³, ¹Internal Medicine, Cook County Hospital, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Systemic Lupus Erythematosus (SLE) a chronic disease, predominantly of young women, which may involve various organs, and is marked by periods of disease flares,…
Abstract Number: 38 • 2015 ACR/ARHP Annual Meeting
Impact of Obesity on the Disease Course of Rheumatoid Arthritis
Yang (Linda) Liu¹, Gilaad Kaplan², Bertus Eksteen³ and Cheryl Barnabe¹, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ³Division of Hepatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Obesity results in a higher risk for the development of rheumatoid arthritis (RA) but is associated with less radiographic damage. The evidence for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].